Aptamers for Targeted Activaton of T Cell-Mediated Immunity

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes compositions and methods that use aptamers (short, single-stranded nucleic acids) as carrier molecules to deliver antigenic peptides specifically to antigen-presenting cells such as dendritic cells. These aptamers are designed to bind specifically to targets on antigen-presenting cells, are internalized into the cells, and have low immunogenicity on their own. Once inside, the conjugated antigenic peptides are processed and presented on MHC molecules, leading to the activation of specific T cell-mediated immune responses, including both CD4+ and CD8+ T cells.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of novel cancer immunotherapies, especially dendritic cell vaccines for solid tumors and other cancers.
• Targeted delivery of antigens for personalized vaccination, including peptide-based vaccine strategies for infectious diseases or autoimmunity.
• Improving the safety and specificity of immunomodulatory therapies by replacing conventional carrier molecules like antibodies with non-immunogenic aptamers.
• Ex vivo or in vivo loading of antigenic peptides onto autologous dendritic cells for cell-based immunotherapies.
• Design of adjuvant-free or reduced-immunogenicity formulations for vaccines or immunotherapies.

BenefitsContent extracted from patent full text and abstract with AI.

• Increased specificity for antigen-presenting cells, resulting in targeted immune system activation and minimizing off-target effects.
• Low immunogenicity of aptamers reduces the risk of adverse immune reactions compared to antibodies, viruses, or nanoparticles.
• Aptamers can be chemically synthesized, leading to batch-to-batch consistency, scalable manufacturing, and reduced production costs.
• Ability to elicit both CD4+ helper and CD8+ cytotoxic T cell responses, enhancing the range and effectiveness of immune activation.
• Versatile platform that allows for customizable modification (e.g., PEGylation, fluorescent tagging) for improved stability, tracking, or pharmacokinetics.
• Potential for use in both prophylactic and therapeutic applications in a broad range of diseases (cancer, infections, autoimmune diseases).

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Compositions comprising aptamers, and methods of thereof as carrier molecules in cell-mediated immunotherapies, and activation of antigen-specific T- cell responses.